Combivent Respimat Patent Expiration

Combivent Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 24 US drug patents filed from 2013 to 2015. Out of these, 5 drug patents are active and 19 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 16, 2030. Details of Combivent Respimat's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341 Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

Active
US7837235 Device for clamping a fluidic component
Mar, 2028

(3 years from now)

Active
US9027967 Device for clamping a fluidic component
Mar, 2027

(2 years from now)

Active
US7396341 Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(1 year, 11 months from now)

Active
US7896264 Microstructured high pressure nozzle with built-in filter function
May, 2025

(7 months from now)

Active
US7284474 Piston-pumping system having o-ring seal properties
Aug, 2024

(a month ago)

Expired
US7988001 Container provided with a pressure equalization opening
Aug, 2021

(3 years ago)

Expired
US6988496 Cartridge for a liquid
Feb, 2020

(4 years ago)

Expired
US7802568 Cartridge for a liquid
Feb, 2019

(5 years ago)

Expired
US6977042 Microstructured filter
Aug, 2018

(6 years ago)

Expired
US6846413 Microstructured filter
Aug, 2018

(6 years ago)

Expired
US6149054 Mechanical counter for a metering apparatus
Dec, 2016

(7 years ago)

Expired
US6453795 Locking mechanism for a spring-actuated device
Dec, 2016

(7 years ago)

Expired
US6726124 Device for producing high pressure in a fluid in miniature
Oct, 2016

(8 years ago)

Expired
US5964416 Device for producing high pressure in a fluid in miniature
Oct, 2016

(8 years ago)

Expired
US6176442 Device for mounting a component exposed to a pressurized fluid
Oct, 2016

(8 years ago)

Expired
US7104470 Device for producing high pressure in a fluid in miniature
Oct, 2016

(8 years ago)

Expired
US7246615 Atomising nozzle and filter and spray generating device
May, 2016

(8 years ago)

Expired
US5662271 Atomizing devices and methods
Sep, 2014

(10 years ago)

Expired
US6007676 Atomizing nozzle and filter and spray generating device
Sep, 2013

(11 years ago)

Expired
US6503362 Atomizing nozzle an filter and spray generating device
Sep, 2013

(11 years ago)

Expired
US5911851 Atomizing nozzle and filter and spray generating device
Sep, 2013

(11 years ago)

Expired
US5472143 Atomising nozzle and filter and spray generation device
Sep, 2013

(11 years ago)

Expired
US5497944 Atomising devices and methods
Mar, 2013

(11 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Combivent Respimat's patents.

Given below is the list of recent legal activities going on the following patents of Combivent Respimat.

Activity Date Patent Number
Patent litigations
Expire Patent 04 Sep, 2023 US7988001
Maintenance Fee Reminder Mailed 20 Mar, 2023 US7988001
Payment of Maintenance Fee, 8th Year, Large Entity 08 Nov, 2022 US9027967
Expire Patent 31 Oct, 2022 US7802568
Payment of Maintenance Fee, 12th Year, Large Entity 17 May, 2022 US7837235
Maintenance Fee Reminder Mailed 16 May, 2022 US7802568
Payment of Maintenance Fee, 8th Year, Large Entity 17 Nov, 2021 US8733341
Payment of Maintenance Fee, 12th Year, Large Entity 30 Dec, 2019 US7396341
Payment of Maintenance Fee, 12th Year, Large Entity 15 Apr, 2019 US7284474
Payment of Maintenance Fee, 8th Year, Large Entity 22 Jan, 2019 US7988001


FDA has granted several exclusivities to Combivent Respimat. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Combivent Respimat, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Combivent Respimat.

Exclusivity Information

Combivent Respimat holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Combivent Respimat's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Combivent Respimat's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Combivent Respimat's generic, the next section provides detailed information on ongoing and past EP oppositions related to Combivent Respimat patents.

Combivent Respimat's Oppositions Filed in EPO

Combivent Respimat has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 12, 2012, by Knorr-Bremse Systeme Für Nutzfahrzeuge Gmbh. This opposition was filed on patent number EP2004006768W. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP2004006768W Apr, 2012 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Revoked


US patents provide insights into the exclusivity only within the United States, but Combivent Respimat is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Combivent Respimat's family patents as well as insights into ongoing legal events on those patents.

Combivent Respimat's Family Patents

Combivent Respimat has patent protection in a total of 37 countries. It's US patent count contributes only to 7.7% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Combivent Respimat.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Combivent Respimat's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 16, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Combivent Respimat Generics:

Albuterol Sulfate; Ipratropium Bromide is the generic name for the brand Combivent Respimat. 9 different companies have already filed for the generic of Combivent Respimat, with Apotex Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Combivent Respimat's generic

How can I launch a generic of Combivent Respimat before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Combivent Respimat's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Combivent Respimat's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Combivent Respimat -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
100 mcg/20 mcg per actuation 30 Mar, 2023 1 16 Oct, 2030

Alternative Brands for Combivent Respimat

There are several other brand drugs using the same active ingredient (Albuterol Sulfate; Ipratropium Bromide) as Combivent Respimat. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Boehringer Ingelheim
Combivent
Norvium Bioscience
Duoneb


Apart from brand drugs containing the same ingredient, some generics have also been filed for Albuterol Sulfate; Ipratropium Bromide, Combivent Respimat's active ingredient. Check the complete list of approved generic manufacturers for Combivent Respimat





About Combivent Respimat

Combivent Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. Combivent Respimat uses Albuterol Sulfate; Ipratropium Bromide as an active ingredient. Combivent Respimat was launched by Boehringer Ingelheim in 2011.

Approval Date:

Combivent Respimat was approved by FDA for market use on 07 October, 2011.

Active Ingredient:

Combivent Respimat uses Albuterol Sulfate; Ipratropium Bromide as the active ingredient. Check out other Drugs and Companies using Albuterol Sulfate; Ipratropium Bromide ingredient

Dosage:

Combivent Respimat is available in spray, metered form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED Prescription INHALATION


Combivent Respimat News

Boehringer Ingelheim Faces New Class Action Lawsuit Alleging Asthma Monopoly

02 May, 2024

See More